CSL Limited (CSL.AX)

ASX · Healthcare · Biotechnology
197.29 AUD-1.28%As of 2026-11-22 · AUD
Last session low 194.56 AUDLast session high 199.51 AUD
52-week low 90.00 AUD52-week high 205.48 AUD
Market cap (USD)
$62.67B
Sector
Healthcare
P/E (TTM)
15.4x
Dividend yield
2.05%

Market data and research context for informational purposes. Not investment advice.

Technical indicators

Indicators from the 2026-11-20 daily bar; Bollinger %B and the average rows compare the latest price with those values. Prices in AUD.

IndicatorValueReading
RSI (14)50.4In the neutral range (30 to 70)
MACD (12, 26, 9)2.88Below its signal line (4.19); histogram -1.30
Bollinger %B (20, 2)30%Inside the bands (194.04 to 204.92)
SMA 20199.48Price is 1.1% below
SMA 50189.42Price is 4.2% above
SMA 200144.69Price is 36.4% above
ATR (20)1.91% of priceAverage true range per day
52-week position93%In the upper part of the 90.00 to 205.48 range

About CSL Limited

CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments.

Latest fiscal yearEnded 2026-06-30: revenue of $15.70B and an operating margin of 19.8%.

More in Biotechnology